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A glycosynthase approach was attempted to
glycodiversify macrolide antibiotics, using DesR, a
family-3 retaining b-glucosidase involved in the
self-resistance mechanism of methymycin produc-
tion. STD-NMRwas used to probe enzyme-substrate
interactions. Analysis of competitive STD-NMR
experiments between erythromycin A and a chro-
mogenic substrate (pNP-b-D-glucose) with the hy-
drolytically inactive nucleophile mutants led us to
discover a family of unprecedented glycosidase
inhibitors. Analysis of kinetic data with wild-type
DesR determined that erythromycin is a competitive
inhibitor of the glucosidase (IC50 = 2.8 ± 0.3 mM and
Ki = 2 ± 0.2 mM) with respect to the hydrolysis of
pNP-b-D-glucose. Comparable inhibitory data was
obtained for clarithromycin; however, the inhibitory
effect of azithromycin was weak and no significant
inhibition was observed with methymycin or D-des-
osamine. This report documents significant inhibition
of glycosidases by macrolide antibiotics and pro-
vides insight into the design of novel glycosidase in-
hibitors based on themacrolactone ring of macrolide
antibiotics.
INTRODUCTION
Macrolide antibiotics have broad bacteriostatic action against
manyGram-positive bacteria and function by binding to the ribo-
some (Sweetman, 2002; Schlunzen et al., 2001). Recently they
have also been considered for nonantimicrobial applications
such as gastrointestinal stimulating (Omura et al., 1985; Arm-
strong et al., 1992; Erbas et al., 1993; Hawkyard and Koerner,
2007), immunomudulatory (Giamarellos-Bourboulis, 2008;
Rubin, 2004), anti-inflammatory (Zalewska-Kaszubska and Gor-
ska, 2001; Culic et al., 2001; White and Simon, 2005; Ianaro
et al., 2000), antitumor (Yatsunami et al., 1999; Wang et al.,
2000), and anti-HIV (San Jose et al., 1997) activities. There are
several ongoing structure-activity relationship and mechanism
of action studies to differentiate these broad ranges of activities.
Macrolide antibiotics (e.g., methymycin, erythromycin, clarithro-Chemistry & Biology 15mycin, azithromycin) are composed, in part, of carbohydrate
functionalities (Figures 1A and 1B) that play important roles in
binding, efficacy, potency, and resistance (Thibodeaux et al.,
2007; Thibodeaux and Liu, 2007; Zhang et al., 2007; Walsh
et al., 2003). Thus, themodification of the carbohydrate function-
alities is an important approach for drug development and dis-
covery (Fu et al., 2003; Mendez and Salas, 2001; Thibodeaux
et al., 2007; Thibodeaux and Liu, 2007; Yang et al., 2004; Griffith
et al., 2005), particularly in view of the prevalence of bacterial
resistance toward many antibacterial drugs (Henninger, 2003;
Coates et al., 2002).
Current strategies for in vitro glycosylation of natural prod-
ucts are multistep chemical synthesis, enzymatic glycosylation
using glycosyltransferases and costly sugar-nucleotide sub-
strates, or reversible glycosidases (Thiem, 1995). To overcome
these limitations, glycosynthase enzymes were engineered
from glycosidases via replacement of the nucleophilic carboxyl-
ate (Asp or Glu) to Ala, Ser, or Gly (Jakeman and Withers, 2002).
Thus, in the presence of suitable glycosyl donors, mimicking
the glycosyl-enzyme adduct, e.g., a-glycosyl fluorides, glyco-
synthase mutants catalyze the formation of a new glycosidic
linkage, without any hydrolytic activity (see Scheme S1 avail-
able online).
Glycosynthases have primarily arisen from endo- or exo-re-
taining b-glycosidases (Hancock et al., 2006) that physiologically
cleave oligo- or polysaccharides, although recently glycosyn-
thase approaches toward glycosphingolipids (Vaughan et al.,
2006), glycosylated flavonoids (Yang et al., 2007), and an invert-
ing glycosidase (Honda andKitaoka, 2006) have been described.
There is no report on glycosylation of macrolide antibiotics using
these catalysts. We identified DesR, a family-3 b-(1-2)-glucosi-
dase (EC # 3.2.1.21) from Streptomyces venezuelae involved in
the self-resistance mechanism for methymycin biosynthesis
(Figure 1B) (Zhao et al., 1998, 2003), as a potential glycosynthase
that would potentially catalyze the formation of a b-(1-2) glyco-
sidic linkage.
It has been known that not all glycosidase nucleophile mutants
function as glycosynthases (Ducros et al., 2003), thus different
techniques have been applied to investigate the efficiency of
these mutants including fluoride-releasing activity (Drone et al.,
2005), external nucleophile rescue experiments (Hommalai
et al., 2007), circular dichroism (Salleh et al., 2006), and X-ray
crystallography analysis (Jahn et al., 2003; Pyetan et al., 2007).
Saturation transfer difference nuclear magnetic spectroscopy
(STD-NMR) is a powerful technique that could be used in, 739–749, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 739
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Glycosidase Inhibition by MacrolidesFigure 1. Structures of Macrolides and the Role of Glucosidase Self-Resistance
(A) Structure of macrolide antibiotics. Reactions catalyzed by DesR-WT.
(B) Production of methymycin from glucosylated precursor.
(C) Release of para-nitrophenolate from a series of pNP-glycosides was measured based upon absorbance at 400 nm (see Figure 2 for structural and kinetic
information).solution for characterization of ligand binding at atomic resolu-
tion; however, it has only rarely been applied to glycosidases
(Wen et al., 2005; Berteau et al., 2003; Haselhorst et al., 2004;
Brecker et al., 2006).
Here we report our attempts toward development of potential
glycosynthases for macrolide antibiotic acceptors from DesR,
and we will describe application of STD-NMR spectroscopy in
analysis of ligand binding with catalytically inactive glycosidase
nucleophile mutants. Our results indicate a new application for
STD-NMR studies in discovery of novel glycosidase inhibitory
effect of macrolide antibiotics.740 Chemistry & Biology 15, 739–749, July 21, 2008 ª2008 ElsevierRESULTS
Analysis of 3D structures of two members of family-3 glycosi-
dases (b-N-acetylhexosaminidase [Williams et al., 2002] and
exo-1,3-1,4-glucanase [Hrmova and Fincher, 2001]) and an
amino acid sequence alignment showed that aspartic acid 273
of DesR was the conserved amino acid and it may play the role
of nucleophile in catalysis (Figure S1). Recombinant DesR-WT
and DesR-D273G, DesR-D273A, DesR-D273S mutants were
prepared by site-directed mutagenesis. They were expressed
using E. coli in soluble form at high levels (ca. 100 mg l1 ofLtd All rights reserved
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icant differences in yields were noticed between the expression
of DesR-WT and any of the mutants. The BugBuster reagent and
protein expression at 20C were essential for preparation of
soluble DesR.
A small library of commercially available pNP-glycosides was
screened against the purified enzymes, and it was discovered
that pNP-b-D-Glc was accepted as a chromogenic substrate
for DesR-WT (Figures 1C, 2A, and 2B). No other pNP-glycosides
were sufficiently active to enable the determination of kinetic
parameters, although low levels of hydrolytic activity were
observed with pNP-a-D-Glc. The optimum pH activity for hydro-
lysis of pNP-b-D-Glc was determined to be bell-shaped, cen-
tered between pH 7.5 and pH 8.5 (Figures 2C and S3), which is
indicative of two ionizable functionalities within the active site
(Scheme S1). The rate of hydrolysis of pNP-b-D-Glc allowed us
to calculate the following kinetic parameters: Km 4.7 ± 0.5 mM,
Vmax 19.1 ± 1 mmol min
1 mg1 (Figure 2B). The DesR-WT spe-
cific activity was 2 U mg1 for hydrolysis of pNP-b-D-Glc and the
enzyme was active for several months at 4C. The enzyme could
tolerate multiple freeze/thaw cycles, up to 10% (vol) ethanol, 500
mM phosphate, and raising assay temperatures to 35C without
significant loss of activity. Time-dependent 1H-NMR studies
confirmed DesR-WT as a retaining b-glucosidase, by monitoring
the hydrolysis of pNP-b-D-Glc in d-PBS (pH7.6). The exclusive
appearance of b-glucopyranose (dH 4.68, J1,2 = 8 Hz) was
observed, while the anomeric proton signal of a-glucopyranose
(dH 5.27, J1,2 = 3.6 Hz) appeared in the later spectra (Figure S4).
Analysis of the hydrolytic activity of the mutants using pNP-b-
D-Glc revealed that the D273G substitution resulted in a loss of
activity (0.2 mU mg1), consistent with data from nucleophile
mutants of other glucosidases (Wang et al., 1994), whereas the
D273A and D273S had no detectable enzyme activity in our
assay conditions. All mutants were also inactive against all
other commercial pNP-glycosides (Figure 2A). A dramatic loss of
hydrolytic activity for the D273 mutants supports the identifica-
tion of D273 as the nucleophilic amino acid catalyst of DesR.
1H-NMR spectra of the wild-type and mutant enzymes were
essentially identical, showing that the mutants were likely prop-
erly folded (Figure S5).
The glycosynthase activity of the three DesR mutants was
tested. No product was produced after incubation of mutants
with GlcF and methymycin or erythromycin (Figure S6). A variety
of conditions were explored, such as varying substrate concen-
trations, incubation times, and temperature or using cosolvents
(ethanol, acetonitrile), with no apparent effect on the result.
Incorporation of other potential acceptors in the assay, as
described in the Experimental Procedures, did not result in
any glycosylation activity. The hydrolysis of GlcF in the absence
or in the presence of the enzymes was examined by 19F-NMR,
to see if water could function as the acceptor (Figure S7). No
significant difference was observed in the rate of hydrolysis
of GlcF by DesR-WT or DesR-D273G, consistent with other
b-(1-3)-glycoside mutants (Drone et al., 2005). In contrast, the
folding of the mutants was further corroborated by external
nucleophile rescue experiments; formate anions were able to
rescue the hydrolytic activity of the serine and glycine mutants
with DNP-b-D-Glc and weakly inhibited DesR-WT activity
(Figures S8 and S9).Chemistry & Biology 1To see whether nonproductive binding configurations of pNP-
b-D-Glc or misfolding of mutants was the reason for the lack of
hydrolytic activity, we probed substrate binding to DesR-WT
and mutants using STD-NMR spectroscopy. Recognition of
the slow substrate, pNP-a-D-Glc, by DesR-WT was determined
through the appearance of STD signals (Figure 3A). Comparable
binding results were obtained from STD-NMR experiments in-
volving pNP-a- and b-D-Glc with the D273S mutant, implying
that hydrolytically competent substrates were also recognized
by the mutant (Figures 3B–3D and S12). An STD-NMR spectrum
from an equimolar mixture of pNP-a- and b-D-Glc interacting
with the D273Smutant indicated that both aryl glycosides bound
(Figure 3D), particularly given the presence of signals from H1
and the ortho substituents of the phenyl rings. The binding of
pNP-a-D-Glc to the wild-type enzyme and D273S mutant was
observed by STD-NMR with comparable intensity; however,
there were subtle differences between the STD-enhancements
observed (Figure S13). In particular, H1 and H5 intensities were
both 23% with the wild-type enzyme, whereas H1 and H5 inten-
sities were both 80% with the D273S mutant.
STD-NMR spectroscopy was applied to probe whether the
fluorosugar and macrolide substrates bound to the mutant en-
zyme. STD-NMR signals were observed for erythromycin and
GlcF, indicating that both compounds were recognized by the
D273S mutant (Figures 4A and 5B). Also, STD-NMR studies
revealed that the interaction between GlcF and the D273S
mutant was greater than with DesR-WT (Figures 4A and 4E).
When a mixture of GlcF and glucose in the presence of the
D273S mutant was analyzed by STD-NMR, only GlcF, not the
aorb formsofglucopyranose, bound to themutant. In theunlikely
event that either glucopyranose form bound as a high-affinity li-
gandwith a slow koff rate (Wang et al., 2004), competition-binding
experiments were performed by titration of glucose into the mix-
ture ofGlcF andD273Smutant (Figures 4B–4D). Signalswere not
observed for either glucopyranose form binding to D273S.
The wild-type enzyme and nucleophile mutant both bound
erythromycin based on STD-NMR results (Figures 5A and 5B).
In an attempt to demonstrate a partially overlapping binding site
for erythromycin and pNP-b-D-Glc, and to rule out nonspecific
interactions, a competitive STD-NMR titration experiment was
performed in which erythromycin was added to a mixture of
pNP-b-D-Glc and the D273S mutant (Figures 5C–5E). However,
the solubility of erythromycin limited the titration. The STD-NMR
signal intensity of pNP-b-D-Glc decreased after addition of eryth-
romycin, indicating that the antibiotic likely competes with pNP-
b-D-Glc in an overlapping binding site. We fully assigned the 1H
NMR spectrum of erythromycin in d-PBS (pH 7.6) at 27C to
determine the binding-epitope of erythromycin using STD-NMR
spectroscopy (Tables S2 and S3). A confounding factor is the ex-
istence of the hemiacetal forms of erythromycin (Barber et al.,
1991). It was determined that the concentration of the 9,12-hemi-
acetal isomer of erythromycin was 2.3 times less than the 9-keto
isomer (FigureS16).Wedetermined that D-desosamineand L-cla-
dinose were found in 4C1 and
1C4 conformations, respectively.
We did not observe a significant STD enhancement with the
9,12-hemiacetal form of erythromycin in 1D 1H-STD-NMR exper-
iments (Figure 6B). Group epitope mapping of erythromycin
bound with DesR-D273S mutant (Figure 6C) was determined
using 2D STD-TOCSY NMR (Figure S15) and revealed that5, 739–749, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 741
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Glycosidase Inhibition by MacrolidesFigure 2. Kinetic Analysis of Wild-Type DesR
(A) Screening of chromogenic substrates with DesR-WT.
(B) Representative kinetic data for the reaction of DesR-WT with pNP-b-D-Glc (Km 4.7 ± 0.5 mM, kcat 19.1 ± 1 mmol min
1 mg1). The assays were performed
as described in the Experimental Procedures using 0.5 mM enzyme. Time-dependent changes were monitored at 400 nm and initial rates were used for kinetic
calculations. Each point was measured in triplicate. (Outer graph) Michaelis-Menten plot: the lines through the points represent the Michaelis-Menten equation
calculated by the GraFit. (Inset) Lineweaver-Burk plot.
(C) pH dependence of the hydrolysis of pNP-b-D-Glc by DesR-WT; the line was added to data points for better visualization.D-desosamine and L-cladinose sugars, as well as the macrolac-
tone ring, were involved in interactions with the enzyme.
Inhibitionstudies indicatedthaterythromycinwasapotentb-glu-
cosidase inhibitor (IC50 = 2.8 ± 0.3 mM) (Figure 7A). Detailed kinetic
analysis determined that erythromycin was a competitive inhibitor
of DesR-WT,with aKi = 2 ± 0.2 mM (Figures 7B and 7C). Two semi-
synthetic macrolides, clarythromycin and azithromycin, which are
more acid stable and exist as a single isomer in aqueous solution
(Awanet al., 1992; Fiese andSteffen, 1990),were examinedasgly-
cosidase inhibitors. Clarythromycin, a 14 membered macrolide,
was also found to be a competitive inhibitor for DesR-WT (IC50
9.7 ± 0.6 mM [Figure 7]; Ki = 6.2 ± 1.2 mM, Ki, [data not shown]),742 Chemistry & Biology 15, 739–749, July 21, 2008 ª2008 Elsevierwhereas azithromycin, a 15 membered macrolide antibiotic that
has the sugars in the same conformations and orientations as in
the erythromycin derivatives (Lazarevski et al., 1993), recorded
an IC50 of 459 ± 88 mM (Figure 7A). Additionally, no significant inhi-
bitionofDesRwasobservedwhen the physiological product of the
enzyme,methymycin, orD-desosamine,wasexaminedup toafinal
concentration of 400 mM and 250 mM, respectively.
DISCUSSION
We identified DesR, a b-(1-2) glucosidase, as a potential glyco-
synthase enzyme that would generate novel macrolideLtd All rights reserved
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that catalyze the formation of b-(1-2) linkages or linkages to
amino sugars. Following the expression and purification of
DesR-WT, we found that pNP-b-D-Glc was a substrate for
DesR-WT, in contrast to its homolog, OleR (Quiros et al.,
1994). Further analysis of DesR-WT catalysis confirmed the en-
zyme was a b-retaining glucosidase with similar pH activity pro-
files for pNP-b-D-Glc and the physiological substrate (Zhao et al.,
2003). The Km for the physiological substrate indicated a 1000-
fold tighter binding affinity than the aryl glucoside, while the
physiological substrate has a 30-fold lower Vmax. Overall, this
results in a 35-fold reduction of Vmax/Km for the aryl glucoside
Figure 3. STD-NMR Spectra of pNP-a- and
pNP-D-Glc Binding to DesR Wild-Type and
to Hydrolytically Inactive Mutant D273S
500 MHz 1H-STD-NMR spectrum in d-PBS (pH
7.6): (A) DesR-WT (0.02 mM) and pNP-a-D-Glc
(2 mM); (B) DesR-D273S (0.02 mM) and pNP-a-D-
Glc (2 mM); (C) DesR-D273S (0.02 mM) and pNP-
b-D-Glc (2 mM); (D) DesR-D273S (0.02 mM),
pNP-b-D-Glc (2 mM), and pNP-a-D-Glc (2 mM).
Figure 4. STD-NMRSpectra of GlcF Binding
to DesR Wild-Type and to Hydrolytically
Inactive Mutant D273S
500 MHz 1H-STD-NMR spectrum of DesR-D273S
(0.1 mM) in d-PBS (pH 7.6) in the presence of (A)
GlcF (20 mM), (B) A + D-Glc (1 mM), (C) A + D-Glc (2
mM), (D) A + D-Glc (20 mM), and (E) 500 MHz 1H-
STD-NMR spectrum of DesR-WT (0.1 mM) and
a mixture of GlcF: a-D-Glc: b-D-Glc (5.2:1:1.5) in
d-PBS (pH 7.6).
(Figure 2A). To the extent that Km is amea-
sure of substrate binding, these results in-
dicate that there ismost likely a significant
interaction between DesR-WT and the
macrolactone ring in the acceptor binding
site. This implies an extended acceptor-
binding site on DesR, since it would be
anticipated that the macrolactone binds
a substantial distance from the active
site catalytic residues. The 30-fold higher
Vmax for the aryl glucoside is likely a result
of the substantial decrease in pKHA of the
p-nitrophenolate relative to the secondary alcohol. A dramatic
loss of hydrolytic activity for the D273mutants supports the iden-
tification of D273 as the nucleophilic amino acid catalyst of
DesR. Further support is given through the rescue experiments
with the nucleophile mutants, where the cleavage of DNP-b-D-
Glc with formate indicated that the mutants were also properly
folded. Moreover, the STD-NMR experiments demonstrated
that erythromycin (Figures 5A and 5B) and pNP-a-D-Glc (Figures
3A and 3B) were recognized by the mutants and the wild-type
enzyme similarly; reconfirming the proper folding of the mutants.
Therefore, the lack of hydrolytic activity with the mutants was
likely due to a change of the catalytic machinery.
Chemistry & Biology 15, 739–749, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 743
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phile mutants bound GlcF (Figure 4A) and erythromycin (Fig-
ure 5B), despite being catalytically inactive in transglycosylation
mode. It also revealed that GlcF binds to the mutants better than
the WT enzyme, supporting the hypothesis that glycosidase nu-
cleophile mutants more efficiently bind GlcF. The incorporation
of an a-fluoro substituent at C1 of glucose is essential for recog-
Figure 5. STD-NMR Spectra of Erythromy-
cin and pNP-b-D-Glc Binding to Hydrolyti-
cally Inactive Mutant D273S
500 MHz 1H-STD-NMR spectrum in d-PBS (pH
7.6): (A) DesR-WT (0.02 mM) and erythromycin
(2 mM), (B) DesR-D273S (0.02 mM) and erythrom-
ycin (2 mM), (C) DesR-D273S (0.02 mM) and pNP-
b-D-Glc (2mM), (D) C + erythromycin (0.1mM), and
(E) C + erythromycin (0.32 mM). NMR signals in
pNP-b-D-Glc that were noticeably suppressed
upon addition of erythromycin are marked by
arrows.
Figure 6. Epitope Mapping of Erythromycin
Bound to Hydrolytically Inactive Mutant
D273S
(A) 500 MHz 1H-NMR spectrum of erythromycin in
d-PBS (pH 7.6); (B) 500 MHz 1H-STD-NMR
spectrum of DesR-D273S (0.1 mM) and erythro-
mycin (2 mM) in d-PBS (pH 7.6), saturation
time 5 s; (C) Epitope mapping of erythromycin A
bound to DesR-D273S in d-PBS (pH 7.6) using
2D STD-TOCSY NMR data. Shaded circles indi-
cate definitive STD enhancement between eryth-
romycin and DesR-D273S.
nition and binding by the nucleophile mu-
tants, since neither the a or b forms of
glucose bind (Figure 4E).
Our STD-NMR data indicate that pNP-
a-D-Glc binds to the wild-type and the
D273Smutant with comparable intensity.
In both instances, signals corresponding
to the carbohydrate and the aryl moiety
were clearly observed. There were
changes in STD signal intensities, relative
to the largest intensities in each differ-
ence spectrum, for particular protons in
pNP-a-D-Glc. The H1 and H5 intensities were both 23% with
the wild-type enzyme, whereas H1 and H5 intensities were
both 80% with the D273S mutant. The intensities for the other
glucoside protons (H2–4, H6) interacting with the wild type and
mutant were similar. Thus, the glucoside binds to both the wild
type and D273S mutant, with more intense interactions occur-
ring between the mutant and both H1 and H5 than with the
744 Chemistry & Biology 15, 739–749, July 21, 2008 ª2008 Elsevier Ltd All rights reserved
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Glycosidase Inhibition by Macrolideswild-type enzyme and these protons. The STD-NMR data for the
D273S mutant indicated that pNP-b-D-Glc and pNP-a-D-Glc
bind with comparable intensity; analysis of the wild-type enzyme
with pNP-b-D-Glc was not attempted due to the rapid hydrolysis
of this substrate.
Erythromycin bound to both the wild-type enzyme and the
D273S mutant with essentially identical STD-NMR spectra. The
interpretation of our STD-NMR data for erythromycin did not
include accounting for the effects of differential relaxation times
of each proton, which has been shown to have an effect upon
quantitative epitope mapping (Yan et al., 2003), due to the signif-
icantly crowded nature of the erythromycin 1H-NMR spectrum.
Thus, the relatively high intensity of the signals arising from the
methyl substituents of erythromycin is not necessarily propor-
tional to the strength of the interaction (Berteau et al., 2003).
However, the signals clearly identified through analysis of the
STD-NMR experiments demonstrated that both sugar rings
and themacrolactone ring of erythromycin were involved in inter-
actions with DesR (Figure 6). It is of significance that the L-cladi-
nose residue interactswith DesR, given that it is not a component
of methymycin, the physiological substrate. Although recogni-
tion of the D-desosamine ring was clear, the lack of an apparent
interaction between the C-20 proton of the D-desosamine ring
and DesR may indicate that the desosamine ring binds in an
incorrect orientation for transglycosylation with GlcF, given that
there is an unequivocal signal for the interaction between C-1
of GlcF and the mutant. Competitive STD-NMR binding experi-
ments between erythromycin and pNP-b-D-Glc with DesR-
D273S led to a reduction in the binding of pNP-b-D-Glc upon
addition of erythromycin (Figures 5C–5E), lending support to
Figure 7. Inhibition of DesR Wild-Type
by Erythromycin and Related Macrolide
Antibiotics
(A) Representative IC50 data for the inhibition of
pNP-b-D-Glc hydrolysis by DesR-WT with C
erythromycin (IC50 = 2.8 ± 0.3 mM),B clarithromy-
cin (IC50 = 9.7 ± 0.6 mM), and : azithromycin
(IC50 = 459 ± 88 mM).
(B and C) Michaelis-Menten plot (B); Lineweaver-
Burk plot (C) (1 mM data have not been shown
for clarity purposes), lines drawn obtained from
nonlinear least-squares fit to the observed data
using Michaelis-Menten equation for competitive
inhibition of erythromycin (Ki = 2.0 ± 0.2 mM).
Inhibition of pNP-b-D-Glc hydrolysis by DesR-WT
(B, no erythromycin; C, 0.001; 7, 0.005; -,
0.01; 6, 0.1; :, 0.2;,, 0.5; and ;, 1 mM). The
final concentration of enzyme was 0.5 mM and
concentrations of pNP-b-D-Glc (S) were between
1.4 and 25 mM.
a hypothesis that these two compounds
share an overlapping binding site.
The interactions observed by STD-
NMR spectroscopy were substantiated
by kinetic analysis. Erythromycin was
determined to be a competitive inhibitor
of DesR-WT in the hydrolysis of pNP-
b-D-Glc (IC50 = 2.8 ± 0.3 mM, Ki = 2 ±
0.2 mM). The relationship between our IC50 and Ki data matches
the theoretical relationship closely (Burlingham and Widlanski,
2003). It is significant to note that no glycosidase inhibitory effect
was previously observed for erythromycin against N-acetyl-b-D-
glucosaminidase and lysozyme (Shiono and Hayasaka, 1985).
The affinity observed by DesR-WT for erythromycin may poten-
tially explain the lack of glycosynthase activity of the mutants by
limiting turnover.
The interaction between the dimethylamino functionality of
desosamine and DesR correlates well with the fact that many
potent glycosidase inhibitors are aminosugars (Winchester and
Fleet, 1992; Dwek et al., 2002) or pseudoaminosugars (Kameda
et al., 1985; Takeuchi et al., 1990); thus, we speculated that the
desosamine ring of macrolide antibiotics may be responsible for
the inhibition of DesR, in an analogous manner to the other
3-aminosugar glycosidase inhibitors (Maxwell et al., 2006). How-
ever, no inhibitory effect was observed at high concentrations
of desosamine alone. Therefore, we turned our attention to the
inhibitory effect of the macrolactone-ring of the antibiotics.
We found a dramatic decrease in the inhibition of DesR by azi-
thromycin and methymycin, macrolides of differing ring size to
erythromycin. These data support the idea that 14 membered
macrolide rings contribute significantly to binding as indicated
by STD-NMR and inhibition studies. Based on crystal structure
and NMR studies of erythromycin, clarithromycin, and azithro-
mycin, it has been known that the region C(3)–C(8), including
the sugars, are almost completely superimposable in 3D struc-
tures with variations existing primarily in the conformation of
C(9)–C(15) (Awan et al., 1995). Our STD-NMR data (Figure 6), to-
gether with glucosidase inhibitory effect of macrolides (Figure 7),
Chemistry & Biology 15, 739–749, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 745
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Glycosidase Inhibition by Macrolidessuggest that C(9)–C(15) may play a critical role in inhibition of
DesR. This study demonstrates the inhibitory effect of macrolide
antibiotics against glycosidases, identifying an alternative class
of cyclic natural product glycosidase inhibitors (Rao et al., 2005).
SIGNIFICANCE
STD-NMR spectroscopy enabled us to monitor binding
of substrates to inactive enzyme variants, providing insight
into the enzyme active site structure and recognition of non-
physiological substrates and inhibitors. The spectroscopic
investigation explained that substrate binding occurs to
glycosidase nucleophile mutants. The lack of glycosynthase
activity was likely attributable to a lack of reactivity or bind-
ing orientation. Competitive STD-NMR experiments identi-
fied that macrolide antibiotics bound to the active site and
subsequent kinetic analysis confirmed that the macrolide
antibiotics act as competitive glycosidase inhibitors.
Whether there is any clinical significance to the inhibition
of glycosidases by macrolide antibiotics remains to be de-
termined. The reported inhibition of a glycosidase by a mac-
rolide antibiotic is important because it represents a new
chemical scaffold with significant glycosidase inhibition.
EXPERIMENTAL PROCEDURES
Identification of Catalytic Nucleophile Amino Acid
Analysis of 3D structures of two family-3 glycosidase enzymes, a b-N-acetyl-
hexosaminidase (EC # 3.2.1.52) (Williams et al., 2002), and an exo-1,3-1,4-glu-
canase (EC # 3.2.1.58) (Hrmova and Fincher, 2001) and an amino acid
sequence alignment (ClustalW [v 1.83]) between DesR, OleR and EryBI (gluco-
sidases involved in self-resistance of oleandomycin in Streptomyces antibioti-
cus (OleR) and erythromycin in Saccharopolyspora erythraea (EryBI)) and other
homologous glycosidases, showed that aspartic acid 273 was conserved
between all proteins (Figure S1).
DesR Mutagenesis
Plasmid pDesR-3 (Zhao et al., 2003) was used as a template for PCR. DesR-
D273G, DesR-D273A, andDesR-D273Smutantswere preparedwith theQuik-
Change II site-directed mutagenesis kit (Stratagene). Mutagenic primers were
synthesized by Integrated DNA Technologies and were designed as follows:
50-GGC TGG GTG ATG TCC GGC T(GG CTA GCC) ACC CCG GGC-30 and
50-GCC CGGGGT (GGC TAG CC)A GCCGGA CAT CAC CCA GCC-30 for mu-
tant D273G; 50-GGC TGG GTG ATG TCC GCC T(GG CTA GCC) ACC CCG
GGC-30and 50-GCC CGG GGT (GGC TAG CC)A GGC GGA CAT CAC CCA
GCC-30 for mutant D273A; 50-GC TGG GTG ATG TCC AGC T(GG CTA GCC)
ACC C-30 and 50-G GGT (GGC TAG CC)A GCT GGA CAT CAC CCA GC-30
for mutant D273S.
A silent mutation was also incorporated into mutagenic primers to create
a new restriction site for NheI (bold letter inside the brackets). PCR was per-
formed using a Biometra Tpersonal machine. For PCR, 5 ml each of the pair
primers (5 mM) were combined with 3 ml DMSO, 5 ml 103 reaction buffer, 1 ml
dNTP mix, 1 ml pDesR-3 (20 ng ml1) and 29 ml sterile distilled water. After 30 s
denaturing at 95C, 1 ml PfuUltra High-Fidelity DNA-polymerase (2.5 U ml1)
was added and thermocycling was started. The first cycle was 95C for 30 s
(denaturing), 55C for 1 min (annealing), and 68C for 7 min (extension), fol-
lowed by 15 repeating cycles. A DpnI-digested PCR product was transformed
into XL1-Blue supercompetent cells. For DesR-D273A and D273S mutants,
the QuikChange kit was modified: Pfu DNA polymerase (5 U) (Bio Basic Inc.)
was used, the annealing temperature was increased to 65C, and NovaBlue
Giga-Singles competent cells (Novagen) were used for transformations. Trans-
formed cells were grown overnight at 37C on Luria–Bertani (LB) agar plates
including kanamycin (50 mg ml1). Resistant colonies were individually grown
overnight in LBmedium supplemented with kanamycin (50 mgml1) on a rotary746 Chemistry & Biology 15, 739–749, July 21, 2008 ª2008 Elseviershaker (250 rpm) at 37C. Plasmid preparationswere performed usingQIAGEN
plasmid purification kits (QIAGEN). Mutants were verified via NheI (NEB)
digestion followed by 1% agarose-gel electrophoresis. Finally, mutations
were confirmed by sequencing of the mutation point using an up-stream
primer (50-GGC CTC CTT CAT GTG TGC-30).
Protein Expression
DesR-WT and all engineered DesR mutants were expressed as N-His6 fusion
proteins from pET28b-based expression plasmids in Escherichia coli
BL21(lDE3) (Novagen). Transformed cells were grown overnight on LB-agar
plates including kanamycin (50 mg ml1). Transformants were grown overnight
in LB medium supplemented with kanamycin (50 mg ml1) on a rotary shaker
(250 rpm) at 30C. Overexpression of proteins was accomplished by transfer-
ring a 5 ml inoculum from the overnight culture to 250 ml fresh LB medium
containing kanamycin (50 mg ml1) and grown (30C) until the optical density
at 600 nm (OD600) reached 0.3. Cultures were cooled to 20
C and incubated
to mid-log phase (OD600 0.5). Isopropyl-b-D-thiogalactopyranoside (IPTG)
was added to a final concentration of 1 mM to induce protein expression.
The cultures were then incubated at 20C for 20 hr. The cells were collected
by centrifugation (4000 3 g, 4C, 60 min) and the obtained wet pellet (10 g
per liter) were resuspended in lysis buffer (5 ml g1). The lysis buffer was
prepared by ten times dilution of BugBuster 103 (Novagen) using 50 mM
phosphate, 300 mM NaCl, 20 mM imidazole at pH 7.6. To the resulting
cell-suspension were added 5 mg lysozyme (20 kU mg1), 1 mg DNase I (de-
oxyribonuclease I, 650 kU mg1), 100 ml phenylmethylsulfonyl fluoride (PMSF,
100 mM) with stirring at RT for 1 hr. The resulting lysate was clarified by cen-
trifugation (13,000 3 g), and the supernatant purified via immobilized affinity
chromatography (Ni-IMAC) at 4C (AKTA purifier 10) on a HiTrap 5ml Chelating
HP column (Amersham Biosciences). A step-wise gradient of imidazole
(25–250 mM) was applied and UV absorbance was monitored at 280 nm.
The desired fractions, as detected by sodium dodecyl sulfate polyacrylamide
gel (SDS-PAGE) analysis, were pooled. Finally, the homogenous samples
were concentrated to 1 ml and washed with PBS (5 3 20 ml) by ultrafiltration
(30003 g at 4C, in Vivaspin-20, 10,000MWCO tubes, VivaScience Sartorious
group). Protein concentrations were calculated via spectrophotometeric
analysis (3280 79,400 M
1 cm1).
Substrate Screening Assay
Substrate screening was performed in 50 mM potassium phosphate buffer
and 145 mM sodium chloride (PBS) (pH 7.6) at 22C with different pNP-glyco-
sides (8 mM) (Figure 2A). Reaction mixtures (180 ml) were preincubated in the
cell holder and reactions were initiated by addition of enzyme solutions (20 ml,
0.5 mM WT or mutants). Substrate hydrolysis was determined by monitoring
absorbance at 400 nm (3= 5350M1 cm1 forp-nitrophenolate) using aMolec-
ular Devices SpectraMax Plus384 plate reader (Figures 1C and 2A).
Enzyme Hydrolytic Activity Assay
Kinetic studies were performed as described above with different concentra-
tions of pNP-b-D-Glc (para-nitrophenyl b-D-glucopyranoside) substrate rang-
ing from 1.4 mM to 25 mM. Continuous assays were repeated in triplicate.
Kinetic parameters (Km and Vmax) were determined by fitting initial velocity
data (determined by Softmax Pro V4.6) to the Michaelis–Menten equation by
GraFit 5.0 (Erithacus Software).
Synthesis of GlcF and DNP-b-D-Glc
GlcF (Yoon and Rhee, 2000; Juenneman et al., 1991) and DNP-b-D-Glc
(Sharma et al., 1995; Ballardie et al., 1973) were synthesized following litera-
ture procedures in 85% and 20% yield, respectively.
Preparation of D-Desosamine Hydrochloride
White crystalline D-desosamine-HCl (200 mg) was obtained from acidic hydro-
lysis of clarithromycin (20 g) according to the similar procedures in the litera-
ture (Wiley, 1962; Woo et al., 1962; Bolton et al., 1961; Jaret et al., 1973). No
efforts were made to optimize the yield.
Thin Layer Chromatography Analysis
TLC was performed on precoated glass-backed silica gel plates (TLC plate
60A, thickness 250 mm) supplied by Silicycle. Chromatograms were initiallyLtd All rights reserved
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permanganate (dip), followed by warming of the TLC plate with a heat gun.
Mobile phases for glycosynthase assays were EtOAc/MeOH/Water 5/2/0.5
or n-propanol/NH3/Water 5/1/1. These plates were additionally visualized
using vanillin spray or iodine vapor.
Mutant Rescue Experiments
Rescue experiments were performed as described above with different con-
centrations of external nucleophiles (0.2–4 M sodium formate or 0.25–2 M
potassium fluoride). Reaction mixtures (120 ml) were made by preincubation
of enzymes (0.5 mM) and external nucleophile in the cell holder followed by ad-
dition of DNP-b-D-Glc (80 ml, 1mM). Substrate hydrolysiswasmonitored at 400
nm and initial velocity data were corrected by subtracting hydrolysis of sub-
strate in the absence of enzyme.
Glycosynthase Assay
To explore glycosynthase activity of all mutants, 4 mM enzymes were incu-
bated with methymycin (20 mM) and GlcF (80 mM) in PBS (pH 7.6) at 37C.
Reaction mixtures were analyzed by TLC in different intervals up to 2 days
and then finally analyzed using HPLC (Dreassi et al., 2000) andmass spectros-
copy (ESI+). Moreover, mutants (0.5 mM) were incubated at RT with GlcF
(80 mM) as the donor glycoside and the following acceptors: erythromycin
(2.6 mM, saturated solution), pNP-b-D-Glc, pNP-a-D-Glc, OMe-b-D-Gal,
methanol, phenol (all at 40 mM concentration).
NMR Experiments
All NMR experimentswere performed on aBruker Avance 500-MHz spectrom-
eter using a 5 mm inverse triple-resonance (1H/13C/15N) probe equipped with
a single axis actively shielded Z-gradient coil. STD (saturation transfer differ-
ence) spectra (Mayer and Meyer, 1999; Mayer andMeyer, 2001) were typically
collected using 32 scans and 4 dummy scans with 32 k total data points
covering a sweep width of 18 ppm. Selective saturation of the protein was
performed using a 50 ms Gaussian pulse train of 86 Hz field strength. The total
saturation time was typically 2 s, unless otherwise specified, and was adjusted
by the number of pulses in the saturation train. An additional delay before sat-
uration was applied to keep the total recovery time constant. The saturated
and reference spectra were acquired sequentially during each individual
scan by creating a pseudo-2D experiment. During each scan, the saturation
frequency switched from on-resonance at 1 ppm to off-resonance at
35 ppm. One spectrum was recorded with an on-resonance signal at 8
ppm that resulted in the same STD-NMR pattern (Figure S14). To improve
the quality of the STD spectra, a 50 ms, 4960 Hz spin-lock (T1rfilter) was
applied to both the on- and off-resonance spectra to eliminate protein back-
ground signals, and a 2 ms spoil gradient was incorporated to destroy
unwantedmagnetization. The spectra were processed using Bruker’s TopSpin
software, v1.3. The on- and off-resonance spectra were processed identically,
using a 2 Hz line broadening function and zero-filling twice before Fourier
Transform. STD spectra were obtained by subtracting the saturated spectrum
from the reference spectrum. Control STD experiments without protein gave
no spectra, indicating that artifacts were negligible. 2D STD-TOCSY spectra
were recorded with 16 scans per t1 increment. A total of 64 t1 increments
were collected, with the difference between the on and off resonance spectra
obtained via the phase cycle. An 80 msMLEV spin-lock was applied. For STD-
NMR experiments, DesR concentrationswere typically 0.02mM, erythromycin
concentrations were 2 mM, and spectra were recorded at 300 K. The proton
and carbon chemical shifts of erythromycin in d-PBS (pH7.6) were assigned
by the combined use of 1D- and 2D-NMR spectra including COSY, DQF-
COSY, NOESY, ROESY, TOCSY, HSQC, HMBC, DEPTQ-135. Hydrolysis of
GlcF was monitored by 19F-NMR spectroscopy according to the literature
procedure (Andre et al., 2001; Albert et al., 2000).
Enzymatic Inhibition Assays
An IC50 for DesR-WT hydrolysis of pNP-b-D-Glc (3.1 mM) was determined by
preincubation (2 min) of the enzyme (0.05 mM) in the prescence of various con-
centrations of erythromycin (5 nM–1 mM), clarithromycin (70 nM–0.2 mM), or
azithromycin (0.32 mM–3.2 mM) under conditions described above. Ki values
for erythromycin and clarithromycin were determined by measuring the initial
velocities at various concentrations of pNP-b-D-Glc (1.4–25 mM) with a rangeChemistry & Biology 15of fixed concentrations of inhibitors. Kinetic data using up to 10 mM inhibitors
followed Michaelis-Menten curvature and were used for calculation of Ki using
Grafit 5.0.
SUPPLEMENTAL DATA
Supplemental data include two schemes, sixteen figures, and three tables and
can be found with this article online at http://www.chembiol.com/cgi/content/
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Note Added in Proof
A recent pH screeningmethod for glycosynthases has recently been published
that may be applicable to the DesR system:
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